[go: up one dir, main page]

DE69225135D1 - Dosierungsform zur verzoegerten wirkstofffreisetzung - Google Patents

Dosierungsform zur verzoegerten wirkstofffreisetzung

Info

Publication number
DE69225135D1
DE69225135D1 DE69225135T DE69225135T DE69225135D1 DE 69225135 D1 DE69225135 D1 DE 69225135D1 DE 69225135 T DE69225135 T DE 69225135T DE 69225135 T DE69225135 T DE 69225135T DE 69225135 D1 DE69225135 D1 DE 69225135D1
Authority
DE
Germany
Prior art keywords
active substance
substance release
dosing form
delayed active
dosage form
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69225135T
Other languages
English (en)
Other versions
DE69225135T2 (de
Inventor
Frank Jao
Patrick Wong
Hoa Huynh
Kathy Mcchesney
Pamela Wat
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alza Corp
Original Assignee
Alza Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alza Corp filed Critical Alza Corp
Application granted granted Critical
Publication of DE69225135D1 publication Critical patent/DE69225135D1/de
Publication of DE69225135T2 publication Critical patent/DE69225135T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/556—Angiotensin converting enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Vascular Medicine (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Valve Device For Special Equipments (AREA)
  • Percussion Or Vibration Massage (AREA)
  • Reciprocating, Oscillating Or Vibrating Motors (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
DE69225135T 1991-06-27 1992-06-26 Dosierungsform zur verzoegerten wirkstofffreisetzung Expired - Lifetime DE69225135T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/722,622 US5160744A (en) 1991-06-27 1991-06-27 Verapmil therapy
PCT/US1992/005455 WO1993000071A1 (en) 1991-06-27 1992-06-26 Dosage form for a delayed drug delivery

Publications (2)

Publication Number Publication Date
DE69225135D1 true DE69225135D1 (de) 1998-05-20
DE69225135T2 DE69225135T2 (de) 1998-08-20

Family

ID=24902641

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69225135T Expired - Lifetime DE69225135T2 (de) 1991-06-27 1992-06-26 Dosierungsform zur verzoegerten wirkstofffreisetzung

Country Status (18)

Country Link
US (1) US5160744A (de)
EP (1) EP0591389B1 (de)
JP (1) JP3718522B2 (de)
KR (1) KR0137731B1 (de)
AT (1) ATE165000T1 (de)
AU (1) AU654871B2 (de)
CA (1) CA2105165C (de)
DE (1) DE69225135T2 (de)
ES (1) ES2114562T3 (de)
FI (1) FI110919B (de)
GR (1) GR3026674T3 (de)
IE (1) IE922122A1 (de)
MX (1) MX9203443A (de)
NO (1) NO306377B1 (de)
NZ (1) NZ243343A (de)
PT (1) PT100635B (de)
WO (1) WO1993000071A1 (de)
ZA (1) ZA924772B (de)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6764697B1 (en) * 1991-06-27 2004-07-20 Alza Corporation System for delaying drug delivery up to seven hours
US6440457B1 (en) * 1993-05-27 2002-08-27 Alza Corporation Method of administering antidepressant dosage form
US5854254A (en) * 1994-03-30 1998-12-29 North Shore University Hospital Male contraceptives
US20040191314A1 (en) * 1994-04-28 2004-09-30 Frank Jao Antiepileptic dosage form and process for protecting antiepileptic drug
ZA953078B (en) * 1994-04-28 1996-01-05 Alza Corp Effective therapy for epilepsies
TW483763B (en) * 1994-09-02 2002-04-21 Astra Ab Pharmaceutical composition comprising of ramipril and dihydropyridine compound
US5922736A (en) * 1995-12-04 1999-07-13 Celegene Corporation Chronic, bolus administration of D-threo methylphenidate
US5837284A (en) * 1995-12-04 1998-11-17 Mehta; Atul M. Delivery of multiple doses of medications
US6486177B2 (en) * 1995-12-04 2002-11-26 Celgene Corporation Methods for treatment of cognitive and menopausal disorders with D-threo methylphenidate
JP2000513356A (ja) * 1996-06-24 2000-10-10 メルク エンド カンパニー インコーポレーテッド エナラプリルとロサルタンの組成物
US5788987A (en) 1997-01-29 1998-08-04 Poli Industria Chimica Spa Methods for treating early morning pathologies
ES2125198B1 (es) * 1997-05-13 1999-11-16 Vita Invest Sa Asociacion a dosis fija de un inhibidor de la enzima convertidora de angiotensina y de un antagonista de los canales de calcio, procedimiento para su preparacion y su utilizacion para el tratamiento de enfermees cardiovasculares.
US6962997B1 (en) * 1997-05-22 2005-11-08 Celgene Corporation Process and intermediates for resolving piperidyl acetamide steroisomers
US8524277B2 (en) * 1998-03-06 2013-09-03 Alza Corporation Extended release dosage form
US6245357B1 (en) 1998-03-06 2001-06-12 Alza Corporation Extended release dosage form
KR100827254B1 (ko) 1998-06-03 2008-05-07 알자 코포레이션 연장된 약물 치료를 제공하기 위한 방법 및 장치
US6524620B2 (en) 1998-07-20 2003-02-25 Andrx Pharmaceuticals, Inc. Diltiazem controlled release formulation and method of manufacture
UA74141C2 (uk) 1998-12-09 2005-11-15 Дж.Д. Сірл Енд Ко. Фармацевтична композиція на основі тонкоподрібненого еплеренону (варіанти), спосіб її одержання та спосіб лікування розладів, опосередкованих альдостероном (варіанти)
US7108866B1 (en) 1999-12-10 2006-09-19 Biovall Laboratories International Srl Chronotherapeutic diltiazem formulations and the administration thereof
US20060153914A1 (en) * 1999-12-10 2006-07-13 Biovail Laboratories International S.R.L. Chronotherapeutic diltiazem formulations and the administration thereof
JP4100910B2 (ja) * 1999-12-23 2008-06-11 ファイザー・プロダクツ・インク ヒドロゲル駆動の薬物剤形
MXPA02006335A (es) 1999-12-23 2002-12-13 Pfizer Prod Inc Forma de dosificacion de farmaco en capas impulsada por hidrogel.
AU2001261434A1 (en) * 2000-05-11 2001-11-26 Pharmacia Corporation Aldosterone antagonist composition for release during aldosterone acrophase
US6488962B1 (en) * 2000-06-20 2002-12-03 Depomed, Inc. Tablet shapes to enhance gastric retention of swellable controlled-release oral dosage forms
US20030185882A1 (en) * 2001-11-06 2003-10-02 Vergez Juan A. Pharmaceutical compositions containing oxybutynin
US8329217B2 (en) 2001-11-06 2012-12-11 Osmotica Kereskedelmi Es Szolgaltato Kft Dual controlled release dosage form
CA2481236A1 (en) * 2002-03-29 2003-10-09 Alza Corporation Volume efficient controlled release dosage form
US20040005359A1 (en) * 2002-06-27 2004-01-08 Cheng Xiu Xiu Controlled release oral dosage form
US20050239830A1 (en) * 2004-04-26 2005-10-27 Vikram Khetani Methods of diminishing co-abuse potential
WO2006046114A2 (en) * 2004-10-25 2006-05-04 Ranbaxy Laboratories Limited Osmotic dosage forms providing ascending drug release, and processes for their preparation
CN101076248A (zh) * 2004-12-09 2007-11-21 塞尔基因公司 使用d－苏型哌甲酯的治疗
DE102005031577A1 (de) 2005-07-06 2007-01-11 Bayer Healthcare Ag Pharmazeutische Darreichungsformen enthaltend eine Wirkstoffkombination von Nifedipin und/oder Nisoldipin und einem Angiotensin-II Antagonisten
DE102008059206A1 (de) 2008-11-27 2010-06-10 Bayer Schering Pharma Aktiengesellschaft Pharmazeutische Darreichungsform enthaltend Nifedipin oder Nisoldipin und einen Angiotensin-II Antagonisten und/oder ein Diuretikum
CN102091052B (zh) * 2009-12-15 2012-11-07 北京协和药厂 双环醇双层渗透泵控释片剂及其制备方法
CN102293760B (zh) * 2011-03-04 2015-03-18 上海医药集团股份有限公司 一种单硝酸异山梨酯择时控释制剂及其制备方法
CA2872542A1 (en) 2012-05-07 2013-11-14 Bayer Pharma Aktiengesellschaft Process for manufacturing a pharmaceutical dosage form comprising nifedipine and candesartan cilexetil
UY34856A (es) 2012-07-03 2013-12-31 Bayer Pharma AG Formas de presentación farmacéuticas que contienen 5-cloro-n-({(5s)-2-oxo-3-[4-(3-oxo-4- morfolinil)-fenil]-1,3-oxazolidin-5-il}-metil)-2-tiofencarboxamida

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3845770A (en) * 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) * 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4093709A (en) * 1975-01-28 1978-06-06 Alza Corporation Drug delivery devices manufactured from poly(orthoesters) and poly(orthocarbonates)
US4318400A (en) * 1980-01-18 1982-03-09 Alza Corporation Medical infusor
US4327725A (en) * 1980-11-25 1982-05-04 Alza Corporation Osmotic device with hydrogel driving member
DE3228502A1 (de) * 1982-07-30 1984-02-02 Behringwerke Ag, 3550 Marburg Verfahren zur herstellung des c1-inaktivators und seine verwendung
US4765989A (en) * 1983-05-11 1988-08-23 Alza Corporation Osmotic device for administering certain drugs
US4612008A (en) * 1983-05-11 1986-09-16 Alza Corporation Osmotic device with dual thermodynamic activity
US4783337A (en) * 1983-05-11 1988-11-08 Alza Corporation Osmotic system comprising plurality of members for dispensing drug
US4863744A (en) * 1984-09-17 1989-09-05 Alza Corporation Intestine drug delivery
US4753802A (en) * 1986-03-19 1988-06-28 Alza Corporation Verapamil dosage form
US4842867A (en) * 1986-05-09 1989-06-27 Alza Corporation Pulsed drug delivery of doxylamine
US4948592A (en) * 1986-05-09 1990-08-14 Alza Corporation Pulsed drug delivery
US4786503A (en) * 1987-04-06 1988-11-22 Alza Corporation Dosage form comprising parallel lamine
US4915954A (en) * 1987-09-03 1990-04-10 Alza Corporation Dosage form for delivering a drug at two different rates
US4946687A (en) * 1987-10-02 1990-08-07 Alza Corporation Dosage form for treating cardiovascular diseases
US4950486A (en) * 1987-10-02 1990-08-21 Alza Corporation Dosage form for treating cardiovascular diseases
US5019397A (en) * 1988-04-21 1991-05-28 Alza Corporation Aqueous emulsion for pharmaceutical dosage form
US4966769A (en) * 1988-06-02 1990-10-30 Alza Corporation Method for delivering dosage form for diltiazem
IL92966A (en) * 1989-01-12 1995-07-31 Pfizer Dispensing devices powered by hydrogel
US5019396A (en) * 1989-05-12 1991-05-28 Alza Corporation Delivery dispenser for treating cardiac arrhythmias
US5156850A (en) * 1990-08-31 1992-10-20 Alza Corporation Dosage form for time-varying patterns of drug delivery

Also Published As

Publication number Publication date
MX9203443A (es) 1992-12-01
PT100635B (pt) 1999-07-30
FI110919B (fi) 2003-04-30
NO934487D0 (no) 1993-12-09
FI935844L (fi) 1993-12-23
JP3718522B2 (ja) 2005-11-24
WO1993000071A1 (en) 1993-01-07
NZ243343A (en) 1994-12-22
KR0137731B1 (ko) 1998-05-15
NO934487L (no) 1993-12-17
PT100635A (pt) 1993-09-30
CA2105165C (en) 2004-03-16
GR3026674T3 (en) 1998-07-31
ZA924772B (en) 1993-03-31
AU654871B2 (en) 1994-11-24
NO306377B1 (no) 1999-11-01
ES2114562T3 (es) 1998-06-01
DE69225135T2 (de) 1998-08-20
JPH06508838A (ja) 1994-10-06
ATE165000T1 (de) 1998-05-15
EP0591389A1 (de) 1994-04-13
AU2255092A (en) 1993-01-25
FI935844A0 (fi) 1993-12-23
US5160744A (en) 1992-11-03
EP0591389B1 (de) 1998-04-15
IE922122A1 (en) 1992-12-30
CA2105165A1 (en) 1992-12-28

Similar Documents

Publication Publication Date Title
DE69225135D1 (de) Dosierungsform zur verzoegerten wirkstofffreisetzung
ATE234602T1 (de) Verabreichungsform zur abgabe von steigenden wirkstoffdosen
ATE96308T1 (de) Dosierform fuer verabreichung in der humanmedizin.
FR2622798B1 (fr) Forme d'apport dose et dispositif osmotique d'administration d'un medicament pour le traitement de maladies cardio-vasculaires
IT8767796A0 (it) Forma farmaceutica di dosaggio per somministrazione orale con erogazione controllata di un ingrediente attivo
ATE94393T1 (de) Dosisform zur oralen verabreichung des hypoglykaemischen glipizids.
DE3868037D1 (de) Pharmazeutische zusammensetzung mit verzoegerter wirkstoffabgabe.
ATE515265T1 (de) Vitamin d und dessen analoge zur behandlung vom tumoren und anderen hyperproliferativen erkrankungen
DK0527835T3 (da) Doseringsform til afgivelse af et anti-Parkinsonmiddel
RU95113492A (ru) Терапевтическая комбинация, содержащая человеческий интерферон, его применение, фармацевтический препарат, упаковка и способ лечения
NO177177C (no) Fremgangsmåte for fremstilling av en flytende doseringsform for oral administrasjon av en farmasöytisk substans
ES2171469T3 (es) Composicion administrada por via nasal y preparacion que la contiene.
BR9802537A (pt) Método para anestesiar um paciente humano antes de cirurgias de porte dose unitária e sistema farmacêutico para administração
NO890186L (no) Fremgangsmaate for fremstilling av en avgivelses- og/ellerdoseringsform for legemiddelaktive stoffer.
NZ229518A (en) Pharmaceutical dosage form for the medication of fish: method of administration and (prophylactic) treatment
RU95101385A (ru) Продукты, содержащие g-csf и tnf связующие протеина
DE69004265D1 (de) Dosisform zur abgabe löslicher oder unlöslicher arzneistoffe.
DE60112584D1 (de) Verfahren zur Herstellung einer flüssigen Dosierungseinheit und Kit
EA199800770A1 (ru) Лекарственный препарат для терапевтического лечения вирусного гепатита
FI930097A7 (fi) Annostusmuoto lääkeaineen antamiseksi vuorokausiterapian toteuttamista varten
BR9912260A (pt) Emplastro contendo um sistema terapêutico transdérmico e dose única para ministração
DK467586D0 (da) Medicindoseringsapparat for afgivelse af forstaevet medicin til inhaleringsluft
DK0863729T3 (da) Implanterbar controlled release-anordning til administration af lægemidler direkte til en indre del af kroppen
KR920700041A (ko) 치료화합물과 그의 조성 및 용도
IT1270592B (it) Formulazione a rilascio modificato per la somministrazione di farmaci antiinfiammatori non steroidei

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
R071 Expiry of right

Ref document number: 591389

Country of ref document: EP